NFKB1 and systemic lupus erythematosus: Dihydroartemisinin blocks Bruton’s tyrosine kinase signaling and its downstream NF-κB and Myc pathways, directly inhibiting B cell activation and differentiation, and decreasing the number of splenic and circulatory B cells, thereby suppressing B cell response and antibody production in systemic lupus erythematosus [131,132].